← Browse by Condition
Medical Condition
diffuse intrinsic pontine glioma
Total Trials
4
Recruiting Now
4
Trial Phases
EARLY_Phase 1, Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for diffuse intrinsic pontine glioma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — diffuse intrinsic pontine glioma Clinical Trials
How many clinical trials are currently recruiting for diffuse intrinsic pontine glioma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for diffuse intrinsic pontine glioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diffuse intrinsic pontine glioma?
diffuse intrinsic pontine glioma research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diffuse intrinsic pontine glioma clinical trial?
Eligibility criteria for diffuse intrinsic pontine glioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 1
Top Sponsors
2 trials
1 trial
1 trial
Recruiting Clinical Trials
NCT04655404 EARLY_Phase 1
Recruiting
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Enrollment
15 pts
Location
United States, Austr...
Sponsor
Nationwide Children's Hospital
NCT05096481 Phase 2
Recruiting
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Enrollment
120 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT04099797 Phase 1
Recruiting
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Enrollment
56 pts
Location
United States
Sponsor
Baylor College of Medicine
NCT05717699 Phase 1
Recruiting
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Enrollment
18 pts
Location
China
Sponsor
Capital Medical University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology